Bi-weekly capecitabine and oxaliplatin plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer
收藏NIAID Data Ecosystem2026-03-07 收录
官方服务：
资源简介：
Interventions: Bi-weekly XELOX+bevacizumab Primary outcome(s): Progression free survival Study Design: Single arm Non-randomized
创建时间：
2012-01-15
